Please login or register to print this page.

Clinical Articles, Lead Article

London Hospital adopts new test for clopidogrel resistance

BMI The London Independent Hospital’s cardiology team announced recently that it has become the first UK hospital to routinely use an all-in-one genetic test (Spartan RX) to identify patients who are resistant to clopidogrel.

The test identifies the gene, CYP2C19*2, which is present in 30% of the world’s population. There is evidence that having this gene can impair the delivery of clopidogrel.1 In patients who have the CYP2C19*2 gene defect, the drug is not fully metabolised by the body into its working state.

The new test allows for the early identification of patients who carry the gene, and adjustment of their treatment accordingly.

Speaking about the launch of the new service, Consultant Cardiologist Dr Charles Knight at BMI The London Independent Hospital commented: “This is an exciting development in terms of improving the risk profiling of cardiac patients and has the potential to allow improved tailoring of therapy. The new Spartan RX test … is the first test of its kind in the UK and has the potential to improve the outcomes of patients having coronary stents”.

“Before a patient undergoes balloon treatment and stenting their medical team can identify if they have an increased risk of further cardiac complications. Spartan RX quickly and accurately delivers a result that can help determine what medication should be prescribed in order to achieve the best results for a patient. Most complications of coronary stenting occur in the first 24 to 48 hours post surgery so having results in one hour is a significant development.”

The system is designed to be operated by nurses and delivers results in one hour from a cheek swab. Speaking about the launch of the new diagnostic test Kirsty Baker, Executive Director at BMI The London Independent Hospital, said that the hospital was “proud to be at the cutting edge of this new technology. As technology advances we need to embrace the latest diagnostic equipment in order to continually develop the level of care we are able to offer”.

“Genetic testing will allow our cardiologists to deliver to our patients tailored treatment plans and we predict that, as this test becomes widespread across the UK, it has the potential to help improve outcomes for our patients,” she continued.

Dr Knight  edit -

Dr Knight (centre) with BMI The London Independent Hospital's Cardiac Team


1. Clopidogrel pathway:

Published on: June 25, 2012

Members Area

Log in or Register now.

 For healthcare professionals only
Angina book sky



Subscribe to our RSS feed


Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.


    None Found


  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.